Altered expression of CD44 and DKK1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma

被引:0
|
作者
T. Darlavoix
W. Seelentag
P. Yan
A. Bachmann
F. T. Bosman
机构
[1] Academic Medical Center,
[2] University of Amsterdam,undefined
[3] Unilabs Lausanne-Cypa,undefined
[4] Laboratory of Cytology and Pathology,undefined
[5] University Institute of Pathology,undefined
[6] University of Lausanne,undefined
来源
Virchows Archiv | 2009年 / 454卷
关键词
Barrett’s esophagus; Esophageal adenocarcinoma; Dysplasia;
D O I
暂无
中图分类号
学科分类号
摘要
Barrett’s esophagus (BE) is an acquired condition in which the normal lining of the esophagus is replaced by intestinal metaplastic epithelium. BE can evolve to esophageal adenocarcinoma (EAC) through low-grade dysplasia (LGD) and high-grade dysplasia (HGD). The only generally accepted marker for increased risk of EAC is the presence of HGD, diagnosed on endoscopic biopsies. More specific markers for the prediction of EAC risk are needed. A tissue microarray was constructed comprising tissue samples from BE, LGD, HGD, and EAC. Marker expression was studied by immunohistochemistry using antibodies against CD44, DKK1, CDX2, COX2, SOX9, OCT1, E-cadherin, and β-catenin. Immunostaining was evaluated semi-quantitatively. CD44 expression decreased in HGD and EAC relative to BE and LGD. DKK1 expression increased in HGD and EAC relative to BE and LDG. CDX2 expression increased in HGD but decreased in EAC. COX2 expression decreased in EAC, and SOX9 expression increased only in the upper crypt epithelial cells in HGD. E-cadherin expression decreased in EAC. Nuclear β-catenin was not significantly different between BE, LGD, and HGD. Loss of CD44 and gain of DKK1 expression characterizes progression from BE and LGD to HGD and EAC, and their altered expression might indicate an increased risk for developing an EAC. This observation warrants inclusion of these immunohistochemically detectable markers in a study with a long patient follow-up.
引用
收藏
页码:629 / 637
页数:8
相关论文
共 50 条
  • [31] Focus on Barrett's esophagus and esophageal adenocarcinoma
    Paulson, TG
    Reid, BJ
    CANCER CELL, 2004, 6 (01) : 11 - 16
  • [32] Sonic hedgehog gene expression in Barrett's esophagus and esophageal adenocarcinoma
    Oh, Daniel S.
    DeMeester, Steven R.
    Mori, Ryutaro
    Kuramochi, Hidekazu
    Hagen, Jeffrey A.
    Lipham, John C.
    Chandrasoma, Parakrama
    Danenberg, Peter V.
    Danenberg, Kathleen D.
    DeMeester, Tom R.
    GASTROENTEROLOGY, 2008, 134 (04) : A150 - A150
  • [33] Advances in Barrett's esophagus and esophageal adenocarcinoma
    Shaheen, NJ
    GASTROENTEROLOGY, 2005, 128 (06) : 1554 - 1566
  • [34] Familial Barrett’s Esophagus and Esophageal Adenocarcinoma
    Joel Gabre
    Amitabh Chak
    Anil Rustgi
    Current Treatment Options in Gastroenterology, 2020, 18 (4) : 616 - 622
  • [35] Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers
    Grady, William M.
    Yu, Ming
    Markowitz, Sanford D.
    Chak, Amitabh
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (12) : 2486 - 2494
  • [36] Biomarkers of esophageal adenocarcinoma and Barrett's esophagus
    McManus, DT
    Olaru, A
    Meltzer, SJ
    CANCER RESEARCH, 2004, 64 (05) : 1561 - 1569
  • [37] MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma
    Kan, Takatsugu
    Meltzer, Stephen J.
    CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (06) : 727 - 732
  • [38] Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma
    Runge, Thomas M.
    Abrams, Julian A.
    Shaheen, Nicholas J.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2015, 44 (02) : 203 - +
  • [39] Endoscopy for Barrett's esophagus and esophageal adenocarcinoma
    Shaheen, N
    AMERICAN FAMILY PHYSICIAN, 2004, 69 (09) : 2060 - 2061
  • [40] Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma
    Bresalier, Robert S.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (08) : 2155 - 2162